CTS-1027: Phase IIb discontinued

The trial was comparing 15, 30 and 60 mg CTS-1027 twice daily for 24 or 48 weeks plus SOC vs. SOC alone in 114 patients with chronic HCV genotype 1 infection who were null-responders to previous SOC therapy. Conatus said it will continue analysis of low-dose CTS-1027 in the open-label, single arm Phase IIa CTS-1027-04 trial, which completed dosing. Final Phase IIa data are expected next quarter. Conatus has exclusive, worldwide rights to CTS-1027 from Roche, which markets Pegasys and Copegus. ...